Hyaluronidase Effect on Infusion Set Life

Inclusion Criteria

• •1. Clinical diagnosis of type 1 diabetes for at least one year and using an insulin pump for at least 3 months
• •2. Total daily insulin dose of at least 0.4 units/kg/day
• •3. The diagnosis of type 1 diabetes is based on the investigator's judgment; C peptide level and antibody determinations are not needed.
• •4. Age 12 to 45 years
• •5. Hemoglobin A1c level less than or equal to 10%
• •6. Willingness to infuse 1 ml of hyaluronidase (Hylenex) into the insulin infusion set after insertion on day 1 and day 3 of the week they are assigned to use hyaluronidase
• •7. Willingness to use a Silhouette or Comfort insulin infusion set throughout the study. The set includes the Duo Infusion Tubing for infusion of hyaluronidase (Hylenex).
• •8. Willingness to eat the same breakfast each morning for the first two weeks of the study
• •9. Willing to take two 500mg tablets of Tylenol Regular Strength and monitor glucose levels at ½, 1, 2, 4, 6, and 8 hours later.
• •10. For females, not currently known to be pregnant
• •11. An understanding of and willingness to follow the protocol and sign the informed consent
• •12. Must be able to understand spoken or written English